Bain Capital Life Sciences Investors’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1,275,552
| Closed | -$37.9M | – | 28 |
|
|
2023
Q3 | $37.9M | Sell |
1,275,552
-1,030,006
| -45% | -$30.6M | 4.24% | 7 |
|
|
2023
Q2 | $41.5M | Hold |
2,305,558
| – | – | 4.28% | 6 |
|
|
2023
Q1 | $37M | Hold |
2,305,558
| – | – | 4.63% | 7 |
|
|
2022
Q4 | $42.2M | Hold |
2,305,558
| – | – | 4.72% | 7 |
|
|
2022
Q3 | $45.3M | Hold |
2,305,558
| – | – | 5.41% | 7 |
|
|
2022
Q2 | $43M | Buy |
2,305,558
+275,857
| +14% | +$5.14M | 5.04% | 7 |
|
|
2022
Q1 | $44.6M | Hold |
2,029,701
| – | – | 4.33% | 7 |
|
|
2021
Q4 | $57.7M | Buy |
2,029,701
+350,000
| +21% | +$9.94M | 4.57% | 7 |
|
|
2021
Q3 | $35.4M | Hold |
1,679,701
| – | – | 2.19% | 13 |
|
|
2021
Q2 | $31.7M | Buy |
1,679,701
+608,273
| +57% | +$11.5M | 2.07% | 11 |
|
|
2021
Q1 | $16.4M | Hold |
1,071,428
| – | – | 0.93% | 20 |
|
|
2020
Q4 | $15.1M | Hold |
1,071,428
| – | – | 0.95% | 17 |
|
|
2020
Q3 | $16.8M | Hold |
1,071,428
| – | – | 1.56% | 16 |
|
|
2020
Q2 | $18.8M | Buy |
+1,071,428
| New | +$18.8M | 1.97% | 12 |
|